Healthpeak Properties Reports Third Quarter 2024 Results and Declares Quarterly Cash Dividend on Common Stock
THIRD QUARTER 2024 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS
-
Net income of
$0.12 per share, Nareit FFO of$0.44 per share, FFO as Adjusted of$0.45 per share, AFFO of$0.41 per share, and Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of 4.1% -
Increased the midpoint of both 2024 FFO as Adjusted and AFFO guidance by
+$0.01 per share, and increased Total Merger-Combined Same-Store Cash (Adjusted) NOI growth guidance by +50 basis points at the midpoint -
Increased expected 2024 merger-related synergies to approximately
$50 million , driven by property management internalization -
Continued strong momentum in life science with 733,000 square feet of lease executions during the third quarter and through
October 24, 2024 :-
Executed 465,000 square feet of lab leases during the third quarter 2024, including a 37,000 square foot lease at
Gateway ; achieved a positive 10% cash rent mark-to-market on renewals -
Executed 268,000 square feet of lab leases in
October 2024 including 205,000 square feet at Portside and 63,000 square feet at Vantage bringing these marquee campuses to approximately 90% and 70% leased, respectively -
Signed letters of intent (“LOI”) on an additional 575,000 square feet of lab leases including 33,000 square feet at
Gateway bringing the development to 42% leased or committed
-
Executed 465,000 square feet of lab leases during the third quarter 2024, including a 37,000 square foot lease at
- Outpatient medical new and renewal lease executions totaled 3 million square feet with 89% retention and positive 10% cash rent mark-to-market on renewals, including the previously announced CommonSpirit renewal
-
Commenced a
$37 million , 79,000 square foot Class A outpatient medical development inKansas City that is 100% pre-leased to HCA -
Promoted
Natalia De Michele to Senior Vice President –Bay Area Market Lead and hiredClaire Donegan Brown as Senior Vice President –Boston Market Lead , both reporting toScott Bohn , Chief Development Officer and Head of Lab -
Net Debt to Adjusted EBITDAre was 5.1x for the quarter ended
September 30, 2024 -
On
October 23, 2024 , Healthpeak's Board of Directors declared a quarterly common stock cash dividend of$0.30 per share to be paid onNovember 15, 2024 , to stockholders of record as of the close of business onNovember 4, 2024 -
Received the
GRESB Green Star designation for the thirteenth consecutive year and recognized for leading governance and corporate impact disclosures by Governance Intelligence and IR Magazine
THIRD QUARTER COMPARISON
|
Three Months Ended
|
|
Three Months Ended
|
||||||||||||
(in thousands, except per share amounts) |
Amount |
|
Per Share |
|
Amount |
|
Per Share |
||||||||
Net income, diluted |
$ |
85,722 |
|
$ |
0.12 |
|
$ |
64,048 |
|
$ |
0.12 |
||||
Nareit FFO, diluted |
|
315,824 |
|
|
|
0.44 |
|
|
|
252,566 |
|
|
|
0.46 |
|
FFO as Adjusted, diluted |
|
320,776 |
|
|
|
0.45 |
|
|
|
251,647 |
|
|
|
0.45 |
|
AFFO, diluted |
|
289,509 |
|
|
|
0.41 |
|
|
|
219,645 |
|
|
|
0.40 |
|
YEAR TO DATE COMPARISON
|
Nine Months Ended
|
|
Nine Months Ended
|
||||||||||||
(in thousands, except per share amounts) |
Amount |
|
Per Share |
|
Amount |
|
Per Share |
||||||||
Net income, diluted |
$ |
238,057 |
|
$ |
0.36 |
|
$ |
233,497 |
|
$ |
0.43 |
||||
Nareit FFO, diluted |
|
797,546 |
|
|
|
1.17 |
|
|
|
730,764 |
|
|
|
1.32 |
|
FFO as Adjusted, diluted |
|
918,665 |
|
|
|
1.35 |
|
|
|
735,067 |
|
|
|
1.33 |
|
AFFO, diluted |
|
814,404 |
|
|
|
1.20 |
|
|
|
652,839 |
|
|
|
1.18 |
|
Nareit FFO, FFO as Adjusted, AFFO, Total Merger-Combined Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "
MERGER-COMBINED SAME-STORE ("SS") OPERATING SUMMARY
The table below outlines the year-over-year three-month and year-to-date Merger-Combined SS Cash (Adjusted) NOI growth.
Year-Over-Year Total Merger-Combined SS Cash (Adjusted) NOI Growth |
|||||
|
Three Month |
|
Year-To-Date |
||
|
SS Growth % |
% of SS |
|
SS Growth % |
% of SS |
Outpatient Medical |
3.4% |
55.0% |
|
3.3% |
55.1% |
Lab |
2.8% |
35.5% |
|
3.1% |
35.1% |
CCRC |
14.2% |
9.5% |
|
20.2% |
9.8% |
Total Merger-Combined SS Cash (Adjusted) NOI |
4.1% |
100.0% |
|
4.6% |
100.0% |
PHYSICIANS REALTY TRUST MERGER INTEGRATION
In September, Healthpeak internalized outpatient medical property management in
Healthpeak now expects to achieve approximately
LIFE SCIENCE LEASING UPDATE
During the third quarter 2024 and through
- During the third quarter 2024, Healthpeak executed 465,000 square feet of lease agreements.
-
From
October 1 to October 24, 2024 , Healthpeak executed an additional 268,000 square feet of lease agreements.
Year-to-date through
Highlights of recent leasing activity at marquee projects includes:
-
Portside (
South San Francisco ): In October, signed a 12.5-year, 205,000 square foot new lease with a private life science company.
The tenant will relocate from its current space within Healthpeak’s portfolio to two full buildings on the Portside campus:
-
1100 Veterans Boulevard : Tenant improvements on the 112,500 square foot building will commence in late 2024 with occupancy expected in the third quarter of 2025.
-
1120 Veterans Boulevard : Tenant improvements on the 92,500 square foot building will commence in mid-2025 with the phase-in of approximately 31,000 square feet of occupancy in each of 2026, 2027, and 2028.
Since 2021, Healthpeak has signed or commenced 854,000 square feet of leases at Portside bringing the campus to approximately 90% leased. The only remaining availabilities on the 960,000 square foot campus are the 73,000 square foot 1140 Veterans building currently in redevelopment and a 33,000 square foot suite at
Healthpeak is also under construction to refresh and modernize Portside's landscaping, entrances, and signage with improvements to pedestrian connectivity to Healthpeak’s adjacent Cove campus and amenities center. Combined, The Cove and Portside campuses create a nearly 2 million square foot contiguous campus at the doorstep of South San Francisco’s prestigious biotech market.
-
Vantage (
South San Francisco ): In October, signed an 8-year, 63,000 square foot lease with a private biotech company.
The tenant will relocate from its current space within Healthpeak’s portfolio after tenant improvements are completed in late 2025. The two-floor lease brings the 346,000 square foot first phase of Vantage to approximately 70% leased.
Additionally, in September, Healthpeak held the grand opening for The Hangar, a 40,000 square foot market-leading tenant amenity center on the Vantage campus. The Hangar features four unique quick-service restaurants, an artisanal coffee bar, a full-service restaurant, a bar and lounge, a fitness center, and a state-of-the-art conference and meeting space. -
Gateway (Sorrento Mesa): In July, signed an 8-year, 37,000 square foot lease with a private biotech company. The lease is expected to commence in the third quarter of 2025. Additionally, in October, Healthpeak signed an LOI for 33,000 square feet with a mid-cap public biotech. Both tenants are new to the Healthpeak portfolio.
The recent leasing activity brings theGateway development to 42% leased or committed.
LIFE SCIENCE MARKET LEADERSHIP UPDATES
Healthpeak today announced the following leadership updates, effective
-
Natalia De Michele will be promoted to Senior Vice President –Bay Area Market Lead , where she will lead all aspects of Healthpeak’s lab leasing, development, and asset management activities in theBay Area . Since joining Healthpeak in 2018,Ms. De Michele has executed over six million square feet of lab leasing transactions. -
Claire Donegan Brown will join Healthpeak inJanuary 2025 as Senior Vice President –Boston Market Lead and assume leadership of the company’s Boston lab portfolio.Ms. Brown brings 12 years of leasing, development, and asset management experience within the Boston market, having formerly worked forGreatland Realty Partners , an owner and developer of lab real estate inBoston , and BXP, a publicly-traded real estate investment trust.
All three market leaders will report to
During the third quarter, Healthpeak added a new development to its program with HCA. The
CORPORATE IMPACT
Healthpeak received the
To learn more about Healthpeak's commitment to responsible business and view our 2023 ESG Corporate Impact Report, please visit www.healthpeak.com/corporate-impact.
DIVIDEND
On
2024 GUIDANCE
We are updating the following guidance ranges for full year 2024:
-
Diluted earnings per common share from
$0.27 –$0.31 to$0.40 –$0.42 -
Diluted Nareit FFO per share from
$1.59 –$1.63 to$1.61 –$1.63 -
Diluted FFO as Adjusted per share from
$1.77 –$1.81 to$1.79 –$1.81 -
Diluted AFFO per share from
$1.54 –$1.58 to$1.56 –$1.58 - Total Merger-Combined Same-Store Cash (Adjusted) NOI growth from 2.75% – 4.25% to 3.5% – 4.5%
These estimates are based on our view of existing market conditions, transaction timing, and other assumptions for the year ending
CONFERENCE CALL INFORMATION
Healthpeak has scheduled a conference call and webcast for
The conference call can be accessed in the following ways:
- Healthpeak’s website: https://ir.healthpeak.com/news-events
- Webcast: https://events.q4inc.com/attendee/713594150. Joining via webcast is recommended for those who will not be asking questions.
- Telephone: The participant dial-in number is (800) 715-9871.
An archive of the webcast will be available on Healthpeak’s website through
ABOUT HEALTHPEAK
FORWARD-LOOKING STATEMENTS
Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, developments, redevelopments, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release, including statements regarding our anticipated synergies from our merger with
Moreover, other risks and uncertainties of which we are not currently aware may also affect our forward-looking statements, and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by us on our website or otherwise. We do not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Consolidated Balance Sheets In thousands, except share and per share data |
|||||||
|
2024 |
|
2023 |
||||
Assets |
|
|
|
||||
Real estate: |
|
|
|
||||
Buildings and improvements |
$ |
16,059,802 |
|
|
$ |
13,329,464 |
|
Development costs and construction in progress |
|
830,310 |
|
|
|
643,217 |
|
Land and improvements |
|
2,927,675 |
|
|
|
2,647,633 |
|
Accumulated depreciation and amortization |
|
(3,925,375 |
) |
|
|
(3,591,951 |
) |
Net real estate |
|
15,892,412 |
|
|
|
13,028,363 |
|
Loans receivable, net of reserves of |
|
677,590 |
|
|
|
218,450 |
|
Investments in and advances to unconsolidated joint ventures |
|
931,844 |
|
|
|
782,853 |
|
Accounts receivable, net of allowance of |
|
64,979 |
|
|
|
55,820 |
|
Cash and cash equivalents |
|
180,430 |
|
|
|
117,635 |
|
Restricted cash |
|
61,615 |
|
|
|
51,388 |
|
Intangible assets, net |
|
898,379 |
|
|
|
314,156 |
|
Assets held for sale, net |
|
— |
|
|
|
117,986 |
|
Right-of-use asset, net |
|
427,711 |
|
|
|
240,155 |
|
Other assets, net |
|
834,806 |
|
|
|
772,044 |
|
Total assets |
$ |
19,969,766 |
|
|
$ |
15,698,850 |
|
|
|
|
|
||||
Liabilities and Equity |
|
|
|
||||
Bank line of credit and commercial paper |
$ |
— |
|
|
$ |
720,000 |
|
Term loans |
|
1,645,748 |
|
|
|
496,824 |
|
Senior unsecured notes |
|
6,557,170 |
|
|
|
5,403,378 |
|
Mortgage debt |
|
380,459 |
|
|
|
256,097 |
|
Intangible liabilities, net |
|
202,857 |
|
|
|
127,380 |
|
Liabilities related to assets held for sale, net |
|
— |
|
|
|
729 |
|
Lease liability |
|
308,277 |
|
|
|
206,743 |
|
Accounts payable, accrued liabilities, and other liabilities |
|
749,881 |
|
|
|
657,196 |
|
Deferred revenue |
|
903,371 |
|
|
|
905,633 |
|
Total liabilities |
|
10,747,763 |
|
|
|
8,773,980 |
|
|
|
|
|
||||
Commitments and contingencies |
|
|
|
||||
|
|
|
|
||||
Redeemable noncontrolling interests |
|
1,318 |
|
|
|
48,828 |
|
|
|
|
|
||||
Common stock, |
|
699,405 |
|
|
|
547,156 |
|
Additional paid-in capital |
|
12,844,634 |
|
|
|
10,405,780 |
|
Cumulative dividends in excess of earnings |
|
(4,968,819 |
) |
|
|
(4,621,861 |
) |
Accumulated other comprehensive income (loss) |
|
(12,381 |
) |
|
|
19,371 |
|
Total stockholders’ equity |
|
8,562,839 |
|
|
|
6,350,446 |
|
|
|
|
|
||||
Joint venture partners |
|
321,949 |
|
|
|
310,998 |
|
Non-managing member unitholders |
|
335,897 |
|
|
|
214,598 |
|
Total noncontrolling interests |
|
657,846 |
|
|
|
525,596 |
|
|
|
|
|
||||
Total equity |
|
9,220,685 |
|
|
|
6,876,042 |
|
|
|
|
|
||||
Total liabilities and equity |
$ |
19,969,766 |
|
|
$ |
15,698,850 |
|
Consolidated Statements of Operations In thousands, except per share data |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Revenues: |
|
|
|
|
|
||||||||||
Rental and related revenues |
$ |
543,251 |
|
|
$ |
417,075 |
|
|
$ |
1,552,065 |
|
|
$ |
1,219,473 |
|
Resident fees and services |
|
142,845 |
|
|
|
133,808 |
|
|
|
422,512 |
|
|
|
391,076 |
|
Interest income and other |
|
14,301 |
|
|
|
5,360 |
|
|
|
27,884 |
|
|
|
16,802 |
|
Total revenues |
|
700,397 |
|
|
|
556,243 |
|
|
|
2,002,461 |
|
|
|
1,627,351 |
|
|
|
|
|
|
|
|
|
||||||||
Costs and expenses: |
|
|
|
|
|
|
|
||||||||
Interest expense |
|
74,105 |
|
|
|
50,510 |
|
|
|
209,922 |
|
|
|
147,547 |
|
Depreciation and amortization |
|
280,019 |
|
|
|
184,559 |
|
|
|
782,736 |
|
|
|
561,357 |
|
Operating |
|
280,279 |
|
|
|
232,734 |
|
|
|
797,835 |
|
|
|
677,659 |
|
General and administrative |
|
23,216 |
|
|
|
23,093 |
|
|
|
73,233 |
|
|
|
73,576 |
|
Transaction and merger-related costs |
|
7,134 |
|
|
|
36 |
|
|
|
122,113 |
|
|
|
3,098 |
|
Impairments and loan loss reserves (recoveries), net |
|
441 |
|
|
|
(550 |
) |
|
|
11,346 |
|
|
|
(156 |
) |
Total costs and expenses |
|
665,194 |
|
|
|
490,382 |
|
|
|
1,997,185 |
|
|
|
1,463,081 |
|
Other income (expense): |
|
|
|
|
|
|
|
||||||||
Gain (loss) on sales of real estate, net |
|
62,325 |
|
|
|
— |
|
|
|
187,624 |
|
|
|
86,463 |
|
Other income (expense), net |
|
982 |
|
|
|
1,481 |
|
|
|
83,502 |
|
|
|
4,208 |
|
Total other income (expense), net |
|
63,307 |
|
|
|
1,481 |
|
|
|
271,126 |
|
|
|
90,671 |
|
|
|
|
|
|
|
|
|
||||||||
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |
|
98,510 |
|
|
|
67,342 |
|
|
|
276,402 |
|
|
|
254,941 |
|
Income tax benefit (expense) |
|
(1,938 |
) |
|
|
(787 |
) |
|
|
(18,364 |
) |
|
|
(2,225 |
) |
Equity income (loss) from unconsolidated joint ventures |
|
(3,834 |
) |
|
|
2,101 |
|
|
|
(1,407 |
) |
|
|
6,646 |
|
Net income (loss) |
|
92,738 |
|
|
|
68,656 |
|
|
|
256,631 |
|
|
|
259,362 |
|
Noncontrolling interests’ share in earnings |
|
(6,866 |
) |
|
|
(4,442 |
) |
|
|
(18,036 |
) |
|
|
(24,297 |
) |
Net income (loss) attributable to |
|
85,872 |
|
|
|
64,214 |
|
|
|
238,595 |
|
|
|
235,065 |
|
Participating securities’ share in earnings |
|
(197 |
) |
|
|
(166 |
) |
|
|
(610 |
) |
|
|
(1,568 |
) |
Net income (loss) applicable to common shares |
$ |
85,675 |
|
|
$ |
64,048 |
|
|
$ |
237,985 |
|
|
$ |
233,497 |
|
|
|
|
|
|
|
|
|
||||||||
Earnings (loss) per common share: |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
0.12 |
|
|
$ |
0.12 |
|
|
$ |
0.36 |
|
|
$ |
0.43 |
|
Diluted |
$ |
0.12 |
|
|
$ |
0.12 |
|
|
$ |
0.36 |
|
|
$ |
0.43 |
|
Weighted average shares outstanding: |
|
|
|
|
|
|
|
||||||||
Basic |
|
699,349 |
|
|
|
547,062 |
|
|
|
667,536 |
|
|
|
546,978 |
|
Diluted |
|
700,146 |
|
|
|
547,331 |
|
|
|
668,096 |
|
|
|
547,247 |
|
Funds From Operations In thousands, except per share data |
||||||||||||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net income (loss) applicable to common shares |
|
$ |
85,675 |
|
|
$ |
64,048 |
|
|
$ |
237,985 |
|
|
$ |
233,497 |
|
Real estate related depreciation and amortization |
|
|
280,019 |
|
|
|
184,559 |
|
|
|
782,736 |
|
|
|
561,357 |
|
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures |
|
|
12,127 |
|
|
|
6,190 |
|
|
|
32,520 |
|
|
|
18,076 |
|
Noncontrolling interests’ share of real estate related depreciation and amortization |
|
|
(4,534 |
) |
|
|
(4,571 |
) |
|
|
(13,705 |
) |
|
|
(14,042 |
) |
Loss (gain) on sales of depreciable real estate, net |
|
|
(62,325 |
) |
|
|
— |
|
|
|
(187,624 |
) |
|
|
(86,463 |
) |
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11,546 |
|
Loss (gain) upon change of control, net(1) |
|
|
430 |
|
|
|
— |
|
|
|
(77,548 |
) |
|
|
(234 |
) |
Taxes associated with real estate dispositions(2) |
|
|
(145 |
) |
|
|
— |
|
|
|
11,512 |
|
|
|
— |
|
Nareit FFO applicable to common shares |
|
|
311,247 |
|
|
|
250,226 |
|
|
|
785,876 |
|
|
|
723,737 |
|
Distributions on dilutive convertible units and other |
|
|
4,577 |
|
|
|
2,340 |
|
|
|
11,670 |
|
|
|
7,027 |
|
Diluted Nareit FFO applicable to common shares |
|
$ |
315,824 |
|
|
$ |
252,566 |
|
|
$ |
797,546 |
|
|
$ |
730,764 |
|
Diluted Nareit FFO per common share |
|
$ |
0.44 |
|
|
$ |
0.46 |
|
|
$ |
1.17 |
|
|
$ |
1.32 |
|
Weighted average shares outstanding - Diluted Nareit FFO |
|
|
714,715 |
|
|
|
554,614 |
|
|
|
681,128 |
|
|
|
554,535 |
|
Impact of adjustments to Nareit FFO: |
|
|
|
|
|
|
|
|
||||||||
Transaction and merger-related items(3) |
|
$ |
2,725 |
|
|
$ |
49 |
|
|
$ |
108,923 |
|
|
$ |
2,993 |
|
Other impairments (recoveries) and other losses (gains), net(4) |
|
|
441 |
|
|
|
(602 |
) |
|
|
11,741 |
|
|
|
557 |
|
Restructuring and severance-related charges |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,368 |
|
Casualty-related charges (recoveries), net(5) |
|
|
1,792 |
|
|
|
(367 |
) |
|
|
588 |
|
|
|
(610 |
) |
Total adjustments |
|
|
4,958 |
|
|
|
(920 |
) |
|
|
121,252 |
|
|
|
4,308 |
|
FFO as Adjusted applicable to common shares |
|
|
316,205 |
|
|
|
249,306 |
|
|
|
907,128 |
|
|
|
728,045 |
|
Distributions on dilutive convertible units and other |
|
|
4,571 |
|
|
|
2,341 |
|
|
|
11,537 |
|
|
|
7,022 |
|
Diluted FFO as Adjusted applicable to common shares |
|
$ |
320,776 |
|
|
$ |
251,647 |
|
|
$ |
918,665 |
|
|
$ |
735,067 |
|
Diluted FFO as Adjusted per common share |
|
$ |
0.45 |
|
|
$ |
0.45 |
|
|
$ |
1.35 |
|
|
$ |
1.33 |
|
Weighted average shares outstanding - Diluted FFO as Adjusted |
|
|
714,715 |
|
|
|
554,614 |
|
|
|
681,128 |
|
|
|
554,535 |
|
_______________________________________ |
||
(1) |
The nine months ended |
|
(2) |
The nine months ended |
|
(3) |
The three and nine months ended |
|
(4) |
The three and nine months ended |
|
(5) |
Casualty-related charges (recoveries), net are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations. |
Adjusted Funds From Operations In thousands, except per share data |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
FFO as Adjusted applicable to common shares |
$ |
316,205 |
|
|
$ |
249,306 |
|
|
$ |
907,128 |
|
|
$ |
728,045 |
|
Stock-based compensation amortization expense |
|
3,755 |
|
|
|
3,434 |
|
|
|
11,935 |
|
|
|
10,966 |
|
Amortization of deferred financing costs and debt discounts (premiums) |
|
7,408 |
|
|
|
3,054 |
|
|
|
19,247 |
|
|
|
8,828 |
|
Straight-line rents(1) |
|
(10,346 |
) |
|
|
(7,279 |
) |
|
|
(32,891 |
) |
|
|
(12,710 |
) |
AFFO capital expenditures |
|
(23,510 |
) |
|
|
(24,031 |
) |
|
|
(76,744 |
) |
|
|
(66,264 |
) |
Deferred income taxes |
|
585 |
|
|
|
(430 |
) |
|
|
2,330 |
|
|
|
(933 |
) |
Amortization of above (below) market lease intangibles, net |
|
(7,887 |
) |
|
|
(5,626 |
) |
|
|
(23,325 |
) |
|
|
(20,267 |
) |
Other AFFO adjustments |
|
(1,277 |
) |
|
|
(1,123 |
) |
|
|
(4,947 |
) |
|
|
(1,852 |
) |
AFFO applicable to common shares |
|
284,933 |
|
|
|
217,305 |
|
|
|
802,733 |
|
|
|
645,813 |
|
Distributions on dilutive convertible units and other |
|
4,576 |
|
|
|
2,340 |
|
|
|
11,671 |
|
|
|
7,026 |
|
Diluted AFFO applicable to common shares |
$ |
289,509 |
|
|
$ |
219,645 |
|
|
$ |
814,404 |
|
|
$ |
652,839 |
|
Diluted AFFO per common share |
$ |
0.41 |
|
|
$ |
0.40 |
|
|
$ |
1.20 |
|
|
$ |
1.18 |
|
Weighted average shares outstanding - Diluted AFFO |
|
714,715 |
|
|
|
554,614 |
|
|
|
681,128 |
|
|
|
554,535 |
|
_______________________________________ |
||
(1) |
The nine months ended |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024131258/en/
Senior Vice President – Investor Relations
720-428-5400
Source: